Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler

... recommended to our patients who are looking for a dermal filler that lasts longer and doesn't require ... is injected with Artefill similar to other dermal fillers with the key difference being its lasting ... feeling results. This is different from temporary dermal fillers that are made of different kinds of ...

Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles

... precisely deliver energy through the skin to the dermal tissue beneath without damaging the epidermis. This gentle heating of the deeper dermal tissue induces collagen denaturization and contraction. As the dermal tissue recovers, new collagen synthesis occurs, ...

Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine

... Trial Demonstrates Increased dermal Penetration of TPM/Lidocaine Compared to Topical ... and burns. This clinical trial compared the dermal penetration and measured the systemic exposure of ... a local analgesic effect. Despite the increase in dermal drug delivery, TPM/lidocaine did not increase the ...

NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP

... Phase 3 clinical trial of NGX-4010, the Company's dermal patch drug candidate, in patients with HIV-distal ... the potential PHN indication. " NGX-4010 is a dermal patch containing capsaicin, a selective ... portfolio is led by product candidate NGX-4010, a dermal patch designed to manage pain associated with ...

RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial

... fold treatments reporting that RADIESSE(R) dermal filler was found to be significantly more effective than Restylane(R), the leading dermal filler on the market worldwide. The results of ... concluded that 1) patients preferred RADIESSE dermal filler two to one over Restylane, 2) ...

Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery

... higher patient satisfaction with its Radiesse(R) dermal filler than reported after treatment with either ... In this first direct comparison study of Radiesse dermal filler against two leading competitors, the ... more satisfied if they received Radiesse dermal filler than other leading fillers tested, ...

Raydiance Collaborates With Rutgers University and Nation's Largest Tissue Bank to Develop Innovative Tissue Processing Approaches

... largest tissue bank, to improve the science of dermal tissue processing. In a first-of-its-kind test, ... we will be able to disrupt and reinvent dermal tissue processing as we know it. This is great ... more efficiently, increasing the supply of scarce dermal tissues. This would result in more usable tissue, ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

... for Qutenza(TM) (formerly NGX-4010), a high concentration capsaicin dermal patch for the management of neuropathic pain in patients with postherpetic ... late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation

... it is a liquid, is expected to be able to address areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. ... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy

... of painful HIV-distal sensory polyneuropathy (HIV-DSP). NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. Previously completed ... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy

... of painful HIV-distal sensory polyneuropathy (HIV-DSP). NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. Previously completed ... late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain ...

NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia

... top-line results from its second pivotal study of NGX-4010, the Company's dermal patch containing the TRPV1 agonist -- synthetic capsaicin -- in patients ... drug application (NDA) filing in the second half of 2008." NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. This is the second ...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the ...

HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study

... of treatment: a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts. Based on in vitro studies, HP802-247 is expected to release various growth and angiogenic factors into the microenvironment of the ...

Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers

... of treatment: a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts. Based on in vitro studies, HP802-247 is expected to release various growth and angiogenic factors into the micro-environment of ...

Research Shows VASER(R) Lipo Results in Excellent Skin Tightening

... retraction is related to treating the layer of fat directly under the skin. This allows the physician to effectively sculpt an area and stimulate the dermal collagen resulting in skin tightening. The precision of the VASER ultrasonic energy allows a physician to safely treat this area to give patients ...

Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection

... Scale (WSRS), a five-point scale to measure visual severity of wrinkles where five is the most severe rating (extreme). 92% of patients were naive to dermal fillers so had no residual effects from earlier treatment. Key findings from the study include: At 18 months, 97% of patients ...

NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

Phosphagenics Announces Initiation of Phase 1 Clinical Trial in Humans for Its Transdermal Lidocaine

... South Australia, under the guidance of Dr. David Foster, as the Principal Investigator. It is an open label, single centre bioavailability trial of dermal and systemic pharmacokinetics in 12 healthy adult volunteers incorporating secondary endpoints of safety and tolerability. The Company expects to ...

338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment

... products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm Medical's lead product is Radiesse(R) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a ...

Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing

... is a selective enzymatic debriding agent that contains 250 collagenase units per gram of white petrolatum USP. It is indicated for debriding chronic dermal ulcers (e.g., pressure ulcers, vascular ulcers, and diabetic ulcers) and severely burned areas. The enzyme collagenase is derived from the ...

NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology

... polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over ...

Wound Management Technologies, Inc. Announces Evidence Based Study

... in institutionalized patients(1) with prevalence rates between 14-24%. "Skin tears can be a significant problem in the elderly due to loss of dermal tissue thickness, as well as other contributing factors such as comprised nutritional status and decreased mobility," said VP of ...

Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.

... GAM technology may have potential utility in several clinical indications where protein therapeutics have had limited success, including treatment of dermal wounds (such as diabetic foot ulcers), therapeutic angiogenesis (pharmacologically inducing new blood vessel growth), and orthopedic products for ...

Miami Plastic Surgeon Offers Hope to Acne Scarred Patients

... dead cells in the plugged sebaceous follicle. The Active FX Laser, in addition to its resurfacing component, also improves acne scars by a process of dermal remodeling. This can take two to four months to be complete, giving patients more dramatic, longer lasting results. ABOUT JULIO GALLO M.D., ....

Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid

... expansion into targeted, non-systemic delivery of drugs. This trial follows a number of pre-clinical studies that demonstrated both an increase in dermal absorption of retinoic acid when formulated with Phosphagenics' proprietary drug delivery platform (TPM), and a significant reduction in irritation ...

Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells

... models has resulted in the increased pace of angiogenesis, as well as increased keratinocyte and extracellular matrix production, all key drivers for dermal repair. U.S. Biotest, founded by Drs. Gere diZerega and Kathleen Rodgers, maintains an expertise in the licensed compound and has ...

New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects

... subjects throughout the study period. Additionally, the trial showed that, unlike the current treatments for onychomycosis, NB-002 had no safety or dermal irritation concerns. Results of a phase 2 clinical trial for onychomycosis are expected in early 2008. In addition to its topical agents, NanoBio ...

Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial

... About Phosphagenics' Transdermal Carrier Technology Phosphagenics' patented transdermal carrier technology (TPM) utilises natural dermal transport mechanisms to rapidly transport small and large molecules across the skin without disrupting or damaging its surface. The Company believes ...

Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results

... About Phosphagenics' Transdermal Carrier Technology Phosphagenics' patented transdermal carrier technology (TPM) utilises natural dermal transport mechanisms to rapidly transport small and large molecules across the skin without disrupting or damaging its surface. The Company believes ...

WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals' CEO

... the discovery and development of novel molecules to accelerate tissue and organ repair. The Company is currently sponsoring five clinical trials for dermal wound healing, ophthalmic wound healing, and cardiovascular protection and regeneration after heart attack. RegeneRx utilizes an outsourcing ...

Laresse Dermal Filler Research Presented at Anti-Aging World Congress

... of the company's research on novel, synthetic dermal fillers is being presented at the Anti-Aging ... 2007. In 2006, FzioMed launched Laresse dermal Filler, the first ultra-smooth, non-permanent, ... Scientific Officer, will present "Novel Synthetic dermal Fillers" at AAMWC on March 24th. His talk will ...

ArteFill 5-Year Data to Be Presented at American Society for Aesthetic Plastic Surgery Annual Meeting

... FDA-approved non-resorbable injectable dermal filler will be presented at the national meeting ... and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known ... treatment, similar to those observed with other dermal fillers, are lumpiness, persistent swelling or ...

NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)

... application of NGX-4010, the Company's novel dermal patch, on pain due to PHN. The primary endpoint ... NGX-4010 NGX-4010 is a physician-administered dermal patch containing a TRPV1 agonist which targets ... portfolio is led by product candidate NGX-4010, a dermal patch designed to manage pain associated with ...

New Phase IV Clinical Study Indicates LidoSite Provides Rheumatology Patients Superior Pain Relief

... study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 percent of patients ... of iontophoresis to administer local anesthetic before skin puncture or dermal procedures meets the TEC criteria."(1) Various Blue Cross/Blue Shield ...

Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting

... that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates ... scientific articles indicating that TB4 is effective in accelerating dermal and corneal wound healing in several animal models, under a variety ...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

... announced today positive results from pre-clinical studies of its TPM-02 dermal drug delivery technology formulated with retinoic acid, a leading ... in the areas of dermatology and cosmetics." In addition to improving the dermal delivery of retinoic acid, Phosphagenics sees broader applications for its ...

Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial

... Iontophoretic Drug Delivery System, dermal patch and a direct current power source with lidocaine and epinephrine (IDDS) SEATTLE, March 20, 2007 /PRNewswire/ -- Dharma ....

Gentium's Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting

... potential of Defibrotide was tested in vitro using a kit with human micro-vascular endothelial cells forming vessel structures across a layer of dermal fibroblasts. The results demonstrated that Defibrotide at concentrations corresponding to pharmacological Defibrotide blood levels (100 (mu)g/mL) ...